159 related articles for article (PubMed ID: 37028510)
1. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema.
Lumry WR; Maurer M; Weller K; Riedl MA; Watt M; Yu M; Devercelli G; Meunier J; Banerji A;
Ann Allergy Asthma Immunol; 2023 Jul; 131(1):101-108.e3. PubMed ID: 37028510
[TBL] [Abstract][Full Text] [Related]
2. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
[TBL] [Abstract][Full Text] [Related]
3. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.
Lumry WR; Weller K; Magerl M; Banerji A; Longhurst HJ; Riedl MA; Lewis HB; Lu P; Devercelli G; Jain G; Maurer M;
Allergy; 2021 Apr; 76(4):1188-1198. PubMed ID: 33258114
[TBL] [Abstract][Full Text] [Related]
4. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
5. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
[TBL] [Abstract][Full Text] [Related]
6. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.
Hioki C; Oda Y; Moriwaki S; Fukunaga A
J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496
[TBL] [Abstract][Full Text] [Related]
7. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
[TBL] [Abstract][Full Text] [Related]
8. Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study.
Maurer M; Lumry WR; Li HH; Aygören-Pürsün E; Busse PJ; Jacobs J; Nurse C; Ahmed MA; Watt M; Yu M;
J Allergy Clin Immunol Pract; 2024 Jan; 12(1):201-211.e6. PubMed ID: 37730089
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
Hide M; Ohsawa I; Nurse C; Yu M;
J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
[TBL] [Abstract][Full Text] [Related]
10. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
[TBL] [Abstract][Full Text] [Related]
11. The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center.
Buttgereit T; Vera Ayala C; Aykanat S; Weller K; Gutsche A; Maurer M; Magerl M
Front Immunol; 2024; 15():1405317. PubMed ID: 38799421
[TBL] [Abstract][Full Text] [Related]
12. Lanadelumab: A Review in Hereditary Angioedema.
Syed YY
Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
14. An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema.
Itzler R; Lumry WR; Sears J; Braverman J; Li Y; Brennan CJ; Koch GG
Orphanet J Rare Dis; 2024 Jun; 19(1):241. PubMed ID: 38909246
[TBL] [Abstract][Full Text] [Related]
15. The Disease Burden and Societal Costs of Hereditary Angioedema.
Fijen LM; Klein PCG; Cohn DM; Kanters TA
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2468-2475.e2. PubMed ID: 36990433
[TBL] [Abstract][Full Text] [Related]
16. Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
[No Abstract] [Full Text] [Related]
17. Lanadelumab to treat hereditary angioedema.
Wedi B
Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies.
Craig TJ; Zaragoza-Urdaz RH; Li HH; Yu M; Ren H; Juethner S; Anderson J;
Allergy Asthma Clin Immunol; 2022 Sep; 18(1):85. PubMed ID: 36153561
[TBL] [Abstract][Full Text] [Related]
19. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
[TBL] [Abstract][Full Text] [Related]
20. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR;
Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
